Quant pattern outlook: similar-pattern analysis indicates negative drift (next day -1.89%, next week -1.69%, next month -3.72%), reinforcing “don’t chase today.”
Options Data
Bearish
Open Interest Put-Call Ratio
Bullish
Option Volume Put-Call Ratio
Positioning (Open Interest): Put OI 4261 vs Call OI 1849; OI put/call 2.3 = bearish/hedged positioning.
Flow (Volume): Put/call volume ratio 0.83 (calls slightly higher than puts today), but total volume is light (55 vs 5d avg 134.2), so today’s flow signal is not very strong.
Volatility: 30D IV ~32.07 vs HV ~18.86; IV percentile ~85 = options are expensive, consistent with elevated event/earnings uncertainty.
Takeaway: sentiment is cautious/defensive overall (heavy put OI) even if today’s prints leaned slightly call-side.
Technical Summary
Sell
5
Buy
6
Positive Catalysts
Revenue beat in the latest earnings print (QDEC 2025 reported 2026-02-05): revenue came in ~403.4M vs ~394.6M expected (top-line resilience).
“Asset value” support narrative: Citi reiterated Buy and raised PT to $290, arguing the teams’ underlying valuations appear discounted in the stock.
Oversold technical condition (very low short-term RSI) could trigger a reflex bounce if support at ~270 holds.
Neutral/Negative Catalysts
implies traders expect/insure against more downside.
Financial Performance
Latest quarter/season (QDEC 2025; reported 2026-02-05 pre-market): EPS 0.34 vs 0.66 est. (material miss), while revenue ~403.4M beat expectations—suggesting costs/expense mix pressured profitability despite solid sales.
Provided snapshot trend (2026/Q1): revenue down -25.99% YoY and gross margin down -6.20% YoY, while net income and EPS improved YoY (less negative). Net: mixed—top-line and margin pressure are the key concern.
Overall growth read: revenue/margin volatility is a headwind near-term, and the market is reacting more to profitability shortfall than to revenue strength.
Growth
Profitability
Efficiency
Analyst Ratings and Price Target Trends
Recent rating/target changes are mixed:
2025-12-16 Citi: Buy maintained; PT raised to $290 (from $285) on underlying team valuation/discount thesis.
2025-12-15 Wolfe: downgraded to Peer Perform (from Outperform), citing limited catalysts unless the Dolan family sells a stake.
Wall Street pros vs cons:
Pros: hard-asset/teams valuation support; secular tailwinds for franchise values.
Cons: catalyst-light story; upside may depend on unlikely corporate action (stake sale), and today’s earnings miss undermines near-term confidence.
Wall Street analysts forecast MSGS stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for MSGS is 250 USD with a low forecast of 220 USD and a high forecast of 290 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
5 Analyst Rating
Wall Street analysts forecast MSGS stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for MSGS is 250 USD with a low forecast of 220 USD and a high forecast of 290 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
2 Buy
3 Hold
0 Sell
Moderate Buy
Current: 273.650
Low
220
Averages
250
High
290
Current: 273.650
Low
220
Averages
250
High
290
Susquehanna
Positive
maintain
$351 -> $356
AI Analysis
2026-02-06
New
Reason
Susquehanna
Price Target
$351 -> $356
AI Analysis
2026-02-06
New
maintain
Positive
Reason
Susquehanna raised the firm's price target on MSG Sports to $356 from $351 and keeps a Positive rating on the shares. The firm said the in-season economics remain steady as 2Q26 results provided a modest beat with growth led by sponsorship and suites backstopped by the Knicks' season tix price hike.
Morgan Stanley
Benjamin Swinburne
Equal Weight
maintain
$220 -> $295
2026-02-06
New
Reason
Morgan Stanley
Benjamin Swinburne
Price Target
$220 -> $295
2026-02-06
New
maintain
Equal Weight
Reason
Morgan Stanley analyst Benjamin Swinburne raised the firm's price target on MSG Sports to $295 from $220 and keeps an Equal Weight rating on the shares. Q2 results were in-line, with per game spending at Madison Square Garden strong, the analyst tells investors in a research note. The firm sees a balanced risk reward in shares here, which have rallied over 35% in the last six months.
Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for MSGS
